Trial Profile
Placebo-Controlled, Randomized, Prospective and Multicenter Trial of Everolimus in Castrated Resistant Prostate Cancer Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 12 Jul 2018 New trial record